Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: Safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00

Annals of Oncology

Volumn 19, Issue 5, 2008, Pages 853-860

  Fountzilas, G ^a   Dafni, U ^b   Gogas, H ^c   Linardou, H ^d   Kalofonos, H P ^e   Briasoulis, E ^f   Pectasides, D ^g   Samantas, E ^h   Bafaloukos, D ^d   Stathopoulos, G P ⁱ   Karina, M ^a   Papadimitriou, C ^c   Skarlos, D ⁱ   Pisanidis, N ^j   Papakostas, P ^k   Markopoulos, C ^c   Tzorakoeleftherakis, E ^e   Dimitrakakis, K ^c   Makrantonakis, P ^l   Xiros, N ^g   Polichronis, A ^m   Varthalitis, I ⁿ   Karanikiotis, C ^o   Dimopoulos, A M ^c   more..

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d METROPOLITAN HOSPITAL   (Greece)

^e UNIVERSITY OF PATRAS   (Greece)

^f UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^g NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^h AGII ANARGIRI CANCER HOSPITAL   (Greece)

ⁱ HENRY DUNANT HOSPITAL   (Greece)

^j IKA Hospital   (Greece)

^k HIPPOKRATION HOSPITAL   (Greece)

^l THEAGENIO CANCER HOSPITAL   (Greece)

^m 6th Social Services Oncological Hospital   (Greece)

ⁿ Chania General Hospital   (Greece)

^o 424 General Army Hospital   (Greece)

more..

Author keywords

Breast cancer; Chemotherapy; Epirubicin; Paclitaxel; Randomized phase III trial; Taxanes

Indexed keywords

ANTIHISTAMINIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; ERYTHROPOIETIN; EXEMESTANE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; HYDROCORTISONE; METHOTREXATE; ONDANSETRON; PACLITAXEL; TAMOXIFEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; BRONCHOPNEUMONIA; BRONCHOSPASM; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENDOMETRIUM CANCER; ERYTHROCYTE TRANSFUSION; FACE ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GRAND MAL SEIZURE; HEALTH CARE ORGANIZATION; HIGH RISK PATIENT; HUMAN; HYPOTENSION; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG CANCER; LUNG DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PAIN; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; ESTROGENS; FEMALE; FLUOROURACIL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; METHOTREXATE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NEOPLASMS, SECOND PRIMARY; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; TAMOXIFEN;

EID: 43249085592     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm539     Document Type: Article

References (25)

1. Ferlay J, Autier P, Boniol M. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18 (3): 581-592.
2. Ravdin PM, Cronin KA, Howlader N. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356 (16): 1670-1674.
3. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 2001; 6 (Suppl 3): 30-35.
4. Trudeau M, Charbonneau F. Gelmon K et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 2005; 6: 886-898.
5. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995; 273: 542-547.
6. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983.
7. Hudis C, Seidman A, Baselga J et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol 1999; 17: 93-100.
8. Fountzilas G, Nicolaides C, Aravantinos G et al. Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and 10 positive axillary lymph nodes. A feasibility study. Oncology 1998; 55: 508-512.
9. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
10. Fountzilas G, Skarlos D, Dafni U et al. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: A randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2005; 16: 1762-1771.
11. Coombes RC, Hall E, Gibson LJ et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004 350: 1081-1092.
12. Moher D. CONSORT: An evolving tool to help Improve the quality of reports of randomized controlled trials. JAMA 1998; 279: 1489-1491.
13. Budman DR, Berry DA, Cirrincione CT et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1998; 90: 1205-1211.
14. Hryniuk W. Dosage parameters in chemotherapy of breast cancer. Breast Dis 2001; 14: 21-30.
15. Piccart-Gebhart W. Mathematics and Oncology: A match for life? J Clin Oncol 2003; 21: 1425-1428.
16. Piedbois P, Serin D, Priou F et al. Dose-dense adjuvant chemotherapy in node-positive breast cancer: Docetaxel followed by epirubicin/ cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Ann Oncol 2007; 18: 57-52.
17. Eiermann W, Pienkowski T, Crown J et al. Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus. doxorubicin and cyclophosphamide followed by docetaxel (AG>T) in Her-2/neu negative early breast cancer patients with positive axillary lymph nodes: Interim analysis of the BCIRG, 005 study (abstract). Breast Can Res Treat 2005; 94 (Suppl 1): (Abstr A1069).
18. Crown JP, Francis P, DiLeo A et al. Docataxel (T) given concurrently with or sequentially to anthracycline-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+) breast cancer (BrCa), in comparison with non-T adjRx: First results of the BIG 2-98 trial at 5 years [abstract]. J Clin Oncol 2006; 24 (18 Suppl): (Abstr LBA519).
19. Burstein HJ, Parker LM, Keshaviah A et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncoll 2005; 23: 8340-8347.
20. Smith TJ, Khatcheresslan J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 1-19.
21. Hershman D, Neugut AI, Jacobson JS at al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99: 196-205.
22. Venturini M, Mastro LD, Aitini E et al. Dose-dense adjuvant chemotherapy in early breast cancer patents: Results from a randomized trial. J Natl Cancer Inst 2005; 97: 1724-1732.
23. Glück S. Adjuvant chemotherapy for early breast cancer: Optimal use of epirubicin. Oncologist 2005; 10: 780-791.
24. Crump M, Tu D, Shepherd L et al. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3066-3071.
25. Praga C, Bergh J, Bliss J et al. Risk of myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005; 23: 4179-4191.